Effect of Rosuvastatin Therapy on Biomarkers of Inflammation and Immune Activation in People With Human Immunodeficiency Virus at Intermediate Cardiovascular Risk

被引：8

作者：

Hearps, Anna C. ^{[1
,2
,3
]}

Angelovich, Thomas A. ^{[1
,4
]}

Trevillyan, Janine M. ^{[2
,3
]}

Wong, Michelle E. ^{[1
,5
]}

Calmy, Alexandra ^{[6
]}

Hoy, Jennifer F. ^{[2
,3
]}

Jaworowski, Anthony ^{[1
,2
,3
,4
]}

机构：

[1] Burnet Inst, Life Sci Discipline, Melbourne, Vic, Australia

[2] Alfred Hosp, Dept Infect Dis, Melbourne, Vic, Australia

[3] Monash Univ, Melbourne, Vic, Australia

[4] RMIT Univ, Sch Hlth & Biomed Sci, Bundoora, Vic, Australia

[5] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia

[6] Geneva Univ Hosp, Div Infect Dis, HIV AIDS Unit, Geneva, Switzerland

来源：

JOURNAL OF INFECTIOUS DISEASES | 2021年 / 224卷 / 04期

基金：

英国医学研究理事会;

关键词：

HIV; rosuvastatin; chronic inflammation; monocytes; immune activation; cardiovascular disease; MONOCYTES; DECREASES; CELL; MEN;

D O I：

10.1093/infdis/jiaa775

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background. Statins may help prevent cardiovascular disease (CVD) in people with human immunodeficiency virus (PWH) with chronic inflammation owing to their pleotropic lipid-lowering and anti-inflammatory properties. Methods. The impact of 48 weeks of rosuvastatin therapy on inflammation and immune activation in a double-blind, placebo-controlled trial in PWH at moderate cardiovascular disease risk was assessed. Results. Rosuvastatin did not alter plasma levels of interleukin 6, soluble tumor necrosis factor receptor type 2, CXCL10, soluble CD14, or soluble vascular cellular adhesion molecule 1 (P >= .1 for all). Proportions of CD16(+) monocyte subsets were increased in PWH receiving rosuvastatin. Conclusions. The potential benefits of statin use in PWH with normal lipid levels requires further clinical outcome research.

引用

页码：667 / 672

页数：6

共 15 条

[1] Monocytes from men living with HIV exhibit heightened atherogenic potential despite long-term viral suppression with antiretroviral therapy [J].

Angelovich, Thomas A. ;

Trevillyan, Janine M. ;

Hoy, Jennifer F. ;

Wong, Michelle E. ;

Agius, Paul A. ;

Hearps, Anna C. ;

Jaworowski, Anthony .

AIDS, 2020, 34 (04) :513-518

[2] High-Density Lipoprotein Particles and Markers of Inflammation and Thrombotic Activity in Patients with Untreated HIV Infection [J].

Baker, Jason ;

Ayenew, Woubeshet ;

Quick, Harrison ;

Hullsiek, Katherine Huppler ;

Tracy, Russell ;

Henry, Keith ;

Duprez, Daniel ;

Neaton, James D. .

JOURNAL OF INFECTIOUS DISEASES, 2010, 201 (02) :285-292

[3] No Evidence for an Association Between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART [J].

Bedimo, Roger J. ;

Mar, Hanna ;

Bosch, Ronald J. ;

Drechsler, Henning ;

Cyktor, Joshua C. ;

Macatangay, Barnard J. C. ;

Lalama, Christina ;

Rinaldo, Charles, Jr. ;

Collier, Ann ;

Godfrey, Catherine ;

Hogg, Evelyn ;

Hensel, Christopher ;

Eron, Joseph J. ;

Mcmahon, Deborah K. ;

Mellors, John W. ;

Tebas, Pablo ;

Gandhi, Rajesh T. .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2019, 82 (02) :E27-E31

[4] Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in treated HIV-infected patients with metabolic syndrome [J].

Calza, Leonardo ;

Colangeli, Vincenzo ;

Borderi, Marco ;

Beci, Giacomo ;

Esposito, Fabio ;

Bon, Isabella ;

Re, Maria Carla ;

Viale, Pierluigi .

INFECTIOUS DISEASES, 2021, 53 (02) :81-88

[5] Tenofovir/Emtricitabine/Efavirenz Plus Rosuvastatin Decrease Serum Levels of Inflammatory Markers More Than Antiretroviral Drugs Alone in Antiretroviral Therapy-Naive HIV-Infected Patients [J].

Calza, Leonardo ;

Vanino, Elisa ;

Salvadori, Caterina ;

Manfredi, Roberto ;

Colangeli, Vincenzo ;

Cascavilla, Alessandra ;

Di Bari, Maria Assunta ;

Motta, Roberto ;

Viale, Pierluigi .

HIV CLINICAL TRIALS, 2014, 15 (01) :1-13

[6] The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study [J].

De Luca, Andrea ;

Donati, Katleen de Gaetano ;

Colafigli, Manuela ;

Cozzi-Lepri, Alessandro ;

De Curtis, Amalia ;

Gori, Andrea ;

Sighinolfi, Laura ;

Giacometti, Andrea ;

Capobianchi, Maria Rosaria ;

D'Avino, Alessandro ;

Iacoviello, Licia ;

Cauda, Roberto ;

Monforte, Antonella D'Arminio .

BMC INFECTIOUS DISEASES, 2013, 13

[7] HMG-CoA reductase inhibitors deplete circulating classical and non-classical monocytes following human heart transplantation [J].

Fildes, J. E. ;

Shaw, S. M. ;

Mitsidou, A. ;

Rogacev, K. ;

Leonard, C. T. ;

Williams, S. G. ;

Yonan, N. .

TRANSPLANT IMMUNOLOGY, 2008, 19 (02) :152-157

[8] Rosuvastatin Reduces Vascular Inflammation and T-cell and Monocyte Activation in HIV-Infected Subjects on Antiretroviral Therapy [J].

Funderburg, Nicholas T. ;

Jiang, Ying ;

Debanne, Sara M. ;

Labbato, Danielle ;

Juchnowski, Steven ;

Ferrari, Brian ;

Clagett, Brian ;

Robinson, Janet ;

Lederman, Michael M. ;

McComsey, Grace A. .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2015, 68 (04) :396-404

[9] Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) [J].

Grinspoon, Steven K. ;

Fitch, Kathleen V. ;

Overton, Edgar Turner ;

Fichtenbaum, Carl J. ;

Zanni, Markella V. ;

Aberg, Judith A. ;

Malvestutto, Carlos ;

Lu, Michael T. ;

Currier, Judith S. ;

Sponseller, Craig A. ;

Waclawiw, Myron ;

Alston-Smith, Beverly ;

Cooper-Arnold, Katharine ;

Klingman, Karin L. ;

Desvigne-Nickens, Patrice ;

Hoffmann, Udo ;

Ribaudo, Heather J. ;

Douglas, Pamela S. .

AMERICAN HEART JOURNAL, 2019, 212 :23-35

[10] How Monocytes Contribute to Increased Risk of Atherosclerosis in Virologically-Suppressed HIV-Positive Individuals Receiving Combination Antiretroviral Therapy [J].

Jaworowski, Anthony ;

Hearps, Anna C. ;

Angelovich, Thomas A. ;

Hoy, Jennifer F. .

FRONTIERS IN IMMUNOLOGY, 2019, 10

← 1 2 →